1, prevention of atrial fibrillation Once atrial fibrillation occurs, with the development of the disease, atrial fibrillation will become more and more difficult to treat due to the structural reconstruction and electrical reconstruction of the atria, so it is necessary to do a good job in the prevention of atrial fibrillation. First of all, developing good habits and maintaining a happy state of mind are the most essential in the prevention of atrial fibrillation. It is important to control weight, increase regular physical activity, and to quit smoking and limit alcohol consumption. Smoking is a clear risk factor for coronary heart disease and lung disease, and studies have shown that the risk of atrial fibrillation in people who smoke is twice as high as in nonsmokers, and quitting smoking can reduce the risk of developing atrial fibrillation. Alcohol consumption can also increase the risk of atrial fibrillation. Alcohol consumption is a clear trigger for the development of atrial fibrillation in some patients, and some studies have shown that the dose of alcohol consumption is associated with the prevalence of atrial fibrillation, with each 10 grams of alcohol intake per day increasing the risk of atrial fibrillation by about 8%. Therefore, smoking and alcohol cessation are very important for the prevention of AF. Second, limit or avoid caffeine-containing substances such as tea, coffee, cola, and some over-the-counter medications, and be cautious with certain medications for coughs or colds, as they may contain stimulants that can promote irregular heart rhythms. In addition, it is important to control the associated risk factors. Patients with hypertension should actively control their blood pressure levels and monitor them frequently to keep them at a reasonable level and reduce fluctuations in blood pressure. Patients with diabetes should bring their blood sugar up to standard through exercise, controlled diet and medication. Patients with coronary heart disease should control lipid levels to prevent myocardial infarction. Patients with heart failure actively control heart failure. Patients with severe heart valve disease need to consider surgery early if they have it. Recent studies suggest that a number of drugs may have a role in preventing the development of atrial fibrillation, including: angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, aldosterone receptor antagonists, statins, and n-3 unsaturated fatty acids. These drugs may prevent the development of atrial fibrillation by reducing atrial ventricular pressure, reducing atrial fibrosis, anti-inflammatory and antioxidant effects. Their effects have been confirmed in some studies, but the exact effect is still controversial. 2. What to pay attention to during treatment and after cure Amiodarone for atrial fibrillation is a double-edged sword. Long-term use of amiodarone may lead to side effects in multiple systems or organs, such as cardiovascular system toxicity, abnormal thyroid function, pulmonary fibrosis and abnormal liver function. Long-term use of amiodarone should be maintained in small doses, and attention should be paid to monitoring blood pressure and heart rate while taking it, with electrocardiograms, thyroid function, liver and kidney function reviewed in 2 to 3 months, and chest X-ray reviewed in 6 months. Once side effects are detected, the dose should be reduced or discontinued. Some patients with atrial fibrillation may have syncope at the same time. First, the cause of syncope should be identified and eliminated as much as possible. If a 24-hour ambulatory electrocardiogram confirms that the syncope is caused by long intervals during the duration of atrial fibrillation or long intervals during atrial fibrillation resumption, the patient is advised to discontinue heart-rate slowing drugs. Minimize activity during atrial fibrillation episodes and adopt a sitting or lying position to prevent syncope from leading to falls when dizziness occurs. If the patient has syncope due to a long interval at the time of transition, radiofrequency ablation of atrial fibrillation is recommended, and syncope will not occur if atrial fibrillation does not recur. If atrial fibrillation surgery is not indicated or fails, a pacemaker may be considered and atrial fibrillation medication may be administered under the protection of the pacemaker. Pacemaker placement may be considered if the syncope is caused by long intervals >5s. What to look for in elderly patients with atrial fibrillation Research data show that the prevalence of atrial fibrillation is about 10% in the 80-year-old population and about 18% in those over 85 years of age. Elderly patients with AF often have multiple comorbidities such as coronary artery disease, heart failure, and diabetes, and often require a combination of medications and have low metabolism of medications, making treatment more difficult. Older patients are more likely to have embolic events, but also have a higher risk of bleeding, and should be monitored frequently and closely for bleeding while taking warfarin. In addition, elderly patients tend to be more sensitive to some drugs that control the ventricular rate, and attention should be paid to measuring blood pressure and heart rate during medication to prevent adverse drug reactions. 3.What are the complications of atrial fibrillation? How to treat? Stroke is the most serious complication of atrial fibrillation. Because the atria of a patient with atrial fibrillation lose their ability to contract effectively, it is difficult to push blood into the ventricles. This allows blood to flow through the atria, and blood clots have the opportunity to form in the atria. The common site of thrombus formation is the left auricle, a pocket of the left atrium. Once the thrombus is dislodged from the atrium and flows with the blood, it can lead to embolism of peripheral vessels, such as mesenteric artery and renal artery embolism, the most serious consequence of which is cerebrovascular embolism and stroke. Studies have shown that ischemic stroke caused by non-valvular atrial fibrillation accounts for 15% to 20% of all ischemic strokes. The prevalence of stroke in patients with atrial fibrillation was 17.5% in a retrospective survey of inpatient cases in some regions of China. Therefore, it is particularly important to prevent ischemic stroke in patients with atrial fibrillation, especially in elderly patients with atrial fibrillation. Commonly used drugs to prevent thrombosis are aspirin and warfarin. Studies have shown that appropriate anticoagulation with warfarin reduces stroke rates in non-valvular atrial fibrillation by approximately 70% and mortality by 26%. In contrast, aspirin reduced the incidence of stroke by only about 26% and the mortality rate by about 10%. Therefore, aspirin is not a substitute for warfarin in patients with atrial fibrillation. However, because the anticoagulant effect of warfarin is affected by many foods and drugs, the need for long-term monitoring of coagulation indicators makes its use limited. At present, new anticoagulants that are being studied and are expected to replace warfarin in the market include: dabigatran, rivaroxaban, apixaban, etc. No monitoring of coagulation indicators is required for taking these drugs. In addition, percutaneous left-ear occlusion can be performed to prevent left-ear thrombosis by implanting a left-ear occlusion device, thus reducing the risk of stroke. So should all patients take warfarin for stroke prevention? The answer is no. Clinically, doctors will score patients according to their risk of embolism, and warfarin will be given to high-risk patients, while low-risk patients may be withheld. These risk factors include: previous history of embolism, transient ischemic attack, age ≥75 years; heart failure or moderate to severe cardiac systolic insufficiency (left ventricular ejection fraction ≤40%), hypertension, diabetes mellitus, female, age 65-74 years, and vascular disease. The more risk factors, the greater the risk of embolism and stroke. In contrast, low-risk patients require only aspirin or no anticoagulants. Stroke begins with early recognition. Some patients experience only transient ischemic attacks, which are usually short-lived, with most resolving completely within minutes to an hour. Patients may experience weakness or numbness in one limb, slurred speech or complete aphasia, or sudden darkness in the eyes. Although they can return to full normalcy, they are a precursor and danger sign for the occurrence of a complete stroke. The common symptoms of stroke are: hemiplegia, which is a weakness or inability to move one limb; hemianesthesia, sudden numbness of one side of the face or limb; hemianopsia, which means that both eyes cannot see on the same side; dysarthria, which means that both eyes cannot see; vertigo, which is accompanied by nausea and vomiting; diplopia, which is a double vision; vii, difficulty in swallowing and choking on water; viii, unstable walking and uncoordinated movements. In addition, if the condition is severe, severe headache or confusion may occur. Sometimes one of the above symptoms appears alone, and sometimes more than one may appear. Patients with atrial fibrillation should seek treatment at the hospital as soon as the early signs of stroke are detected, and should not delay the diagnosis and treatment by thinking that “it may be fine if I rest at home” or “I will go back when I am better”. This will only delay the diagnosis and treatment and will not benefit the patient in any way. Irreversible changes may occur in normal brain tissue after 3 hours of ischemia, and necrosis of ischemic brain cells may occur after 6 hours. If a patient with cerebral infarction is treated with clot lysis within 3 to 6 hours, it is possible to restore oxygen and blood supply before complete infarction of brain cells occurs, thus restoring all or part of the function. This is currently the only proven treatment option.